No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
01548 GENSCRIPT BIO
- 12.540
- +2.540+25.40%
Not Open Jul 15 16:09 CST
26.68BMarket Cap-35726P/E (TTM)
13.280High11.500Low80.94MVolume11.500Open10.000Pre Close1.01BTurnover3.80%Turnover RatioLossP/E (Static)2.13BShares24.95052wk High2.45P/B26.68BFloat Cap7.43052wk Low--Dividend TTM2.13BShs Float43.400Historical High--Dividend LFY17.80%Amplitude1.058Historical Low12.421Avg Price2000Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hong Kong stock market closed on 07/15, with the Hang Seng Index falling by 1.52%. Network technology stocks were generally under pressure, while digital currency ETFs and golden industrial concept stocks rose against the trend.
Hong Kong's three major indexes fluctuated down all day, with the Hengkang index falling more than 3% in the afternoon and the Hang Seng Index barely holding onto the 18,000 level. At the close, the Hang Seng index fell 1.52% or 277.44 points to 18015.94 points.
Genscript Bio (01548): Unusual fluctuations in stock price and volume, reasons unknown.
Genscript Bio (01548) has released an announcement, and the board of directors of the company has noticed that the company's stock price and volume have recently...
Genscript Bio (01548) opened 15% higher, and according to rumors, Legend Biotech received a merger invitation.
Zhixun Finance App learned that Genscript Bio (01548) opened 15% higher. Its subsidiary Legend Biotech rose 12% last Friday. As of press time, it rose 15% to HKD 11.5, and the turnover was HKD 3.9426 million. According to a report by an anonymous source quoted by Street Insider last Friday, Legend Biotech recently received a takeover invitation and hired investment bank Centerview Partners to assist its board of directors in reviewing the takeover offer and other options. In the transaction where AstraZeneca acquired WuXi Biologics last year for $1.2 billion,
Genscript Biotech Insiders Sold US$11m Of Shares Suggesting Hesitancy
Over the past year, many Genscript Biotech Corporation (HKG:1548) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions,
Hong Kong stocks rebounded again, with pharmaceutical stocks rising, and the industry's investment and financing are expected to hit bottom and rebound. The release of innovative drug policies has provided bullish signals.
According to the Zhongtong Finance APP, pharmaceutical stocks have risen again. As of press time, Kexing Biotech-B (06990) rose 9.07%, reporting HKD 155.1; Zai Lab (09688) rose 4.63%, reporting HKD 14.02; Genscript Biotech (01548) rose 4.59%, reporting HKD 10.02; and Innocare (09969) rose 4.57%, reporting HKD 5.03. On the news front, the US June CPI slowed down more than expected, pushing the probability of a rate cut in September to nearly 90%. Pacific Securities pointed out that as the Fed's rate hike cycle comes to an end in the future, liquidity is expected to gradually ease.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
July 11th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and FRONTAGE
Comments
Genscript Biotech's high P/S ratio is due to its promising revenue outlook. The company's strong performance and bright future are likely to keep supporting the share price unless conditions change.
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce 2
GenScript's leadership values Dr. Liu's expertise in genome editing, chemistry, and synthetic biology for its potential to offer key insights. His addition to the SAB is anticipated to boost GenScript's platform and hasten transformative breakthroughs for patients.
Dr. June joining GenScript's SAB could provide invaluable insights for their initiatives, especially in cell and gene therapy. His expertise may accelerate the development of novel therapies.
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Despite Genscript Biotech's promising revenue outlook, its P/S ratio isn't higher than industry peers due to potential volatility in revenue forecasts. Investors should note the company's 2 warning signs.
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg